Cardio Diagnostics Secures Japanese Patent for AI-Driven Cardiovascular Disease Detection Technology
CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings Inc. (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced that the Japan Patent Office has issued a patent for another set of biomarkers in the company's intellectual property portfolio. The patent, titled 'Compositions and Methods for Detecting Predisposition to Cardiovascular Disease,' (Japanese Patent No. 7672192) is exclusively licensed to Cardio Diagnostics from the University of Iowa Research Foundation (UIRF) and names Cardio Diagnostics' founders Meesha Dogan, Ph.D., Chief Executive Officer, and Robert Philibert, MD, Ph.D., Chief Medical Officer, as inventors.
The Japanese patent further strengthens Cardio Diagnostics' global IP strategy and adds to its robust portfolio of issued patents in the United States, Europe, Australia, India, and China, covering core technologies that helped yield the Company's clinical solutions.
'Receiving this patent in Japan marks a critical milestone in our mission to globalize our precision cardiovascular medicine platform,' said Meesha Dogan, Ph.D., CEO of Cardio Diagnostics. 'As cardiovascular disease continues to rise in prevalence worldwide, the ability to offer AI-powered, methylation- and genetics-based diagnostics in international markets like Japan represents a major step forward in improving early detection and prevention of heart disease.'
'We are proud to support this important innovation from the University of Iowa ecosystem,' said Marie Kerbeshian, Ph.D., Executive Director of the UIRF. 'Cardio Diagnostics continues to demonstrate the global relevance of its technology, and we look forward to the impact it will have in advancing cardiovascular medicine across borders.'
The Japanese patent protects Cardio Diagnostics' novel methods and compositions that enable the detection of cardiovascular disease risk and presence using epigenetic and genetic biomarkers interpreted through advanced machine learning algorithms. This issuance underscores the global applicability of the Company's pioneering approach to heart disease prevention.
As part of its expanding IP footprint, Cardio Diagnostics is committed to delivering innovative, data-driven solutions that empower healthcare providers and patients with actionable insights for cardiovascular health, now on a global scale.
About Cardio Diagnostics
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine ('Core Technology') for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit https://cdio.ai/
Forward-Looking Statements
Certain statements and information included in this press release constitute 'forward-looking statements' within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases 'will', 'will likely result,' 'expected to,' 'will continue,' 'anticipated,' 'estimate,' 'projected,' 'intend,' 'goal,' or similar expressions are intended to identify 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on results are discussed in the Current Report on Form 10-K for the period ended in December 31, 2024, and Form 10-Q for the period ended in March 31, 2025, under the heading 'Risk Factors' in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
7 minutes ago
- Associated Press
Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025
CAMBRIDGE, MA / ACCESS Newswire / June 11, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor event: Barclays Speaking the Science Call Series, on Monday, June 16th at 10:00am ET A live webcast of this presentation will be available under 'Events and Presentations' in the Investors section of the Moderna website. A replay of this webcast will be archived on Moderna's website for at least 30 days following the presentation. About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Investors: Lavina Talukdar Senior Vice President & Head of Investor Relations 617-209-5834 [email protected] SOURCE: Moderna, Inc. press release
Associated Press
7 minutes ago
- Associated Press
EBC Financial Group Launches over a 100 U.S. ETF CFDs, Strengthening Diversification for Global Clients
LONDON, June 11, 2025 (GLOBE NEWSWIRE) -- EBC Financial Group (EBC) has announced the launch of over 100 new U.S.-listed Exchange-Traded Fund (ETF) CFDs, expanding its multi-asset product suite and offering global client's deeper access to diversified, thematic trading opportunities. The rollout highlights EBC's ongoing commitment to delivering institutional-grade tools across asset classes, underpinned by flexibility, transparency, and efficiency. The new offering includes ETFs listed on the NYSE and NASDAQ, issued by leading asset managers such as Vanguard, iShares (BlackRock), and State Street Global Advisors. Thematic coverage spans a wide range of global macro and sectoral narratives. 'This expansion reflects our vision to bridge intelligent product design with market relevance,' said David Barrett, CEO of EBC Financial Group (UK) Ltd. 'The new products are a natural evolution for traders seeking targeted exposure with greater strategic flexibility. At EBC, we're building an ecosystem that empowers both precision and performance.' Thematic Access Meets Tactical Flexibility The additional ETF-linked instruments cover a variety of market exposures, including geographic allocations like the iShares MSCI Brazil ETF; fixed income-focused strategies such as the iShares iBoxx $ High Yield Corporate Bond Fund; and sector- or commodity-based indices including the United States Oil Fund LP and the Vanguard Health Care ETF. Other themes include dividend-related baskets, mid-cap equities, and style-based index tracking. These developments reflect wider industry interest in instruments that mirror trends in asset allocation without direct ownership of the underlying securities. Across many markets, sector-tilted and style-based index products are gaining relevance as participants seek flexible ways to align with global narratives. Historically, ETFs tracking specific economic cycles—such as commodity recoveries or emerging market rebounds—have demonstrated performance differentiation. The iShares MSCI Brazil ETF, for example, notably outperformed the S&P 500 during the post-pandemic recovery period in 2021, highlighting how thematic instruments can diverge from broad indices depending on market cycles. These additions serve as both stand-alone trade ideas and complementary instruments alongside EBC's existing product lineup, enabling advanced portfolio structuring and thematic trading. Smarter Exposure: Leverage, Shorting, and Cost Efficiency in One Product Compared to direct ETF investments, it presents several key advantages as traders benefit from a simplified cost structure, with no traditional fund management fees or broker commissions. The flexibility to take both long and short positions allows for strategic trading regardless of market direction, while the use of leverage enhances capital efficiency and return potential. These trades are executed in real time via EBC's recognised platforms, providing seamless access to market opportunities. During key market cycles, for example the post-pandemic V-shaped recovery of 2021—certain thematic ETFs, like the iShares MSCI Brazil ETF, significantly outperformed broader indices such as the S&P 500. Our portfolio enables traders to participate in similar trends, adapting quickly to shifting market dynamics with precision and speed. Getting Started These products can be accessed by registering on to begin simulated or live trading. About EBC Financial Group Founded in London's esteemed financial district, EBC Financial Group (EBC) is a global brand known for its expertise in financial brokerage and asset management. Through its regulated entities operating across major financial jurisdictions—including the UK, Australia, the Cayman Islands, Mauritius, and others—EBC enables retail, professional, and institutional investors to access a wide range of global markets and trading opportunities, including currencies, commodities, shares, and indices. Recognised with multiple awards, EBC is committed to upholding ethical standards and is licensed and regulated within the respective jurisdictions. EBC Financial Group (UK) Limited is regulated by the UK's Financial Conduct Authority (FCA); EBC Financial Group (Cayman) Limited is regulated by the Cayman Islands Monetary Authority (CIMA); EBC Financial Group (Australia) Pty Ltd, and EBC Asset Management Pty Ltd are regulated by Australia's Securities and Investments Commission (ASIC); EBC Financial (MU) Ltd is authorised and regulated by the Financial Services Commission Mauritius (FSC). At the core of EBC are a team of industry veterans with over 40 years of experience in major financial institutions. Having navigated key economic cycles from the Plaza Accord and 2015 Swiss franc crisis to the market upheavals of the COVID-19 pandemic. We foster a culture where integrity, respect, and client asset security are paramount, ensuring that every investor relationship is handled with the utmost seriousness it deserves. As the Official Foreign Exchange Partner of FC Barcelona, EBC provides specialised services across Asia, LATAM, the Middle East, Africa, and Oceania. Through its partnership with United to Beat Malaria, the company contributes to global health initiatives. EBC also supports the 'What Economists Really Do' public engagement series by Oxford University's Department of Economics, helping to demystify economics and its application to major societal challenges, fostering greater public understanding and dialogue. Media Contact: Savitha Ravindran Global Public Relations Manager s[email protected] Michelle Siow Brand & Communications Director [email protected]
Associated Press
7 minutes ago
- Associated Press
Nebius and Saturn Cloud Launch First-in-Class AI MLOps Cloud with Support for NVIDIA AI Enterprise
Amsterdam, Netherlands--(Newsfile Corp. - June 11, 2025) - Leading AI infrastructure provider Nebius (NASDAQ: NBIS) is partnering with Saturn Cloud, the MLOps platform for AI/ML engineers, to deliver a turnkey AI/ML infrastructure solution built on NVIDIA Hopper GPUs and with support for the NVIDIA AI Enterprise software stack. The solution brings together the power and flexibility of Nebius's AI cloud with Saturn Cloud's engineer-loved MLOps platform. It enables anyone to sign up instantly to use Jupyter notebooks or other IDEs, run jobs and deployments, and manage cloud resources on NVIDIA Hopper GPUs via Nebius's infrastructure. The service is available at significantly lower cost than traditional cloud service providers, providing a compelling solution for all types of use cases. Companies can deploy an enterprise-grade application of Saturn Cloud in a Nebius virtual private cloud environment, compliant with enterprise IT security standards, as well as access to powerful, cost-efficient GPUs. This is complete with enterprise-grade SLAs, single sign-on (SSO), and other IT security integrations that can be found on the respective company documentation pages. Additionally, individuals and teams can join 100,000+ users of Saturn Cloud's hosted tiers, which leverage Nebius hardware to enable instantaneous sign up and deployment of cloud resources. By just providing a credit card, users can benefit from the competitive pricing of Nebius's AI cloud with the full suite of Saturn Cloud's MLOps tool chain. In addition to competitive pricing and fully integrated MLOps, the solution offers access to Nebius's AI Cloud accelerated by NVIDIA. Teams can harness the computational power driving today's most sophisticated AI systems without making long-term investments in accelerated computing systems. Capacity reservations are also possible and deliver additional cost-savings. 'The combination of Nebius's full-stack AI infrastructure and Saturn Cloud's MLOps platform opens up access to enterprise-grade AI capabilities for organizations of all sizes,' said Danila Shtan, CTO of Nebius. 'Nebius offers Saturn Cloud customers flexible access to highly performant, built-for-AI cloud at high levels of reliability and cost efficiency.' 'Together, Nebius and Saturn Cloud enable organizations to become AI-driven,' said M. Sebastian Metti, CEO of Saturn Cloud. 'Previously limited by GPU economics or DevOps, our customers can build and run scalable, GPU-accelerated AI workloads without significant financial or engineering investment.' Beyond cost-effective access to powerful compute, the offering enhances Saturn Cloud's MLOps platform with support for NVIDIA AI Enterprise software, including NVIDIA NIM microservices, NVIDIA NeMo, NVIDIA RAPIDS, and much more, all running on Nebius's high-performance infrastructure. The joint solution is now generally available to customers globally. AI developers can access these capabilities immediately by signing up for Saturn Cloud Pro and start developing on NVIDIA Hopper GPUs in minutes. Enterprise deployments are also available for teams who would like to use Saturn Cloud within their Nebius accounts. About Nebius Nebius is a technology company building full-stack cloud infrastructure to serve the global AI industry, including large-scale GPU clusters, cloud platforms, and tools and services for developers. Headquartered in Amsterdam and listed on Nasdaq, Nebius has a global footprint with R&D hubs across Europe, North America and Israel. The team includes around 400 highly skilled hardware and software engineers, as well as an in-house AI R&D team. Nebius's AI cloud platform delivers a true hyperscale cloud experience for AI innovators. With fully featured cloud software and hardware designed in-house, Nebius gives AI builders the compute, storage, managed services and tools they need to build, tune and run models and apps in one place. To learn more please visit About Saturn Cloud Saturn Cloud is the world's only MLOps platform with a multi-cloud offering of GPUs on-demand. AI/ML and data science teams can now simplify the development, deployment, and management of machine learning models at scale – all at an affordable price, with no commitment required. Contacts Nebius: [email protected] Saturn Cloud: [email protected] To view the source version of this press release, please visit
